

Morten Hoyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11997934/publications.pdf>

Version: 2024-02-01

17
papers

4,124
citations

586496

16
h-index

993246

17
g-index

17
all docs

17
docs citations

17
times ranked

4360
citing authors

#	ARTICLE	IF	CITATIONS
1	Current practice in proton therapy delivery in adult cancer patients across Europe. <i>Radiotherapy and Oncology</i> , 2022, 167, 7-13.	0.3	23
2	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 235-245.	5.1	88
3	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. <i>Radiotherapy and Oncology</i> , 2020, 148, 157-166.	0.3	352
4	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. <i>World Journal of Urology</i> , 2019, 37, 2607-2613.	1.2	18
5	Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 385-395.	6.3	542
6	ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 11-17.	0.3	230
7	Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. <i>European Urology</i> , 2016, 70, 684-691.	0.9	71
8	Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience. <i>Acta OncolÅ³gica</i> , 2015, 54, 1096-1104.	0.8	66
9	Advances in radiotherapy: from 2D to 4D. <i>Cancer Imaging</i> , 2011, 11, S145-S152.	1.2	5
10	NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. <i>Acta OncolÅ³gica</i> , 2011, 50, 518-527.	0.8	31
11	Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-“Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3290-3296.	0.8	780
12	Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. <i>Lancet</i> , The, 2009, 373, 301-308.	6.3	789
13	Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – A first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. <i>Radiotherapy and Oncology</i> , 2008, 88, 359-367.	0.3	129
14	Prospective study on stereotactic radiotherapy of limited-stage non-“small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S128-S135.	0.4	78
15	Phase II study on stereotactic body radiotherapy of colorectal metastases. <i>Acta OncolÅ³gica</i> , 2006, 45, 823-830.	0.8	379
16	Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. <i>Acta OncolÅ³gica</i> , 2006, 45, 787-795.	0.8	220
17	Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. <i>Radiotherapy and Oncology</i> , 2005, 76, 48-53.	0.3	323